Published in FEMS Immunol Med Microbiol on July 15, 2003
S-layers: principles and applications. FEMS Microbiol Rev (2014) 1.02
Bacterial ghosts as an oral vaccine: a single dose of Escherichia coli O157:H7 bacterial ghosts protects mice against lethal challenge. Infect Immun (2005) 1.02
The Bacterial Ghost platform system: production and applications. Bioeng Bugs (2011) 1.00
Recombinant glycans on an S-layer self-assembly protein: a new dimension for nanopatterned biomaterials. Small (2008) 0.97
Vaccines for Nontypeable Haemophilus influenzae: the Future Is Now. Clin Vaccine Immunol (2015) 0.94
S-layer fusion proteins--construction principles and applications. Curr Opin Biotechnol (2011) 0.94
Positively selected codons in immune-exposed loops of the vaccine candidate OMP-P1 of Haemophilus influenzae. J Mol Evol (2007) 0.84
Bacterial ghosts as adjuvants: mechanisms and potential. Vet Res (2017) 0.75
Enteropathogens and chronic illness in returning travelers. N Engl J Med (2013) 2.89
Nontypeable Haemophilus influenzae as a pathogen in children. Pediatr Infect Dis J (2009) 2.12
Aurantimonas coralicida gen. nov., sp. nov., the causative agent of white plague type II on Caribbean scleractinian corals. Int J Syst Evol Microbiol (2003) 1.68
Haemophilus influenzae oral vaccination for preventing acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease. Cochrane Database Syst Rev (2014) 1.45
A novel recombinant multisubunit vaccine against Chlamydia. J Immunol (2004) 1.34
Lactobacillus fermentum (PCC®) supplementation and gastrointestinal and respiratory-tract illness symptoms: a randomised control trial in athletes. Nutr J (2011) 1.29
Impact of saliva collection methods on sIgA and cortisol assays and acceptability to participants. J Immunol Methods (2005) 1.22
Application of broad-range 16S rRNA PCR amplification and DGGE fingerprinting for detection of tick-infecting bacteria. J Microbiol Methods (2003) 1.21
Bacterial ghosts as vaccine candidates for veterinary applications. J Control Release (2002) 1.18
Microarray-based identification of bacteria in clinical samples by solid-phase PCR amplification of 23S ribosomal DNA sequences. J Clin Microbiol (2004) 1.16
Emended descriptions of the genus Micrococcus, Micrococcus luteus (Cohn 1872) and Micrococcus lylae (Kloos et al. 1974). Int J Syst Evol Microbiol (2002) 1.12
Microbial pattern recognition receptors mediate M-cell uptake of a gram-negative bacterium. Infect Immun (2006) 1.05
Bacterial otitis media: a vaccine preventable disease? Vaccine (2005) 1.05
Monitoring the colonization of monuments by bacteria: cultivation versus molecular methods. Environ Microbiol (2003) 1.04
Genome-wide mapping of cystitis due to Streptococcus agalactiae and Escherichia coli in mice identifies a unique bladder transcriptome that signifies pathogen-specific antimicrobial defense against urinary tract infection. Infect Immun (2012) 1.04
Bacterial ghosts as an oral vaccine: a single dose of Escherichia coli O157:H7 bacterial ghosts protects mice against lethal challenge. Infect Immun (2005) 1.02
Phylogenetic 16S rRNA analysis reveals the presence of complex and partly unknown bacterial communities in Tito Bustillo cave, Spain, and on its Palaeolithic paintings. Environ Microbiol (2002) 1.01
Generation of Helicobacter pylori ghosts by PhiX protein E-mediated inactivation and their evaluation as vaccine candidates. Infect Immun (2003) 1.01
The incidence of Streptococcus pneumoniae otitis media is affected by the polymicrobial environment particularly Moraxella catarrhalis in a mouse nasal colonisation model. Microbes Infect (2009) 1.00
The Bacterial Ghost platform system: production and applications. Bioeng Bugs (2011) 1.00
Bacterial ghosts as carrier and targeting systems for mucosal antigen delivery. Expert Rev Vaccines (2003) 0.99
Recombinant Vibrio cholerae ghosts as a delivery vehicle for vaccinating against Chlamydia trachomatis. Vaccine (2003) 0.99
Immunogenicity and protection against genital Chlamydia infection and its complications by a multisubunit candidate vaccine. J Microbiol Immunol Infect (2007) 0.99
Phylogenetic diversity of bacteria associated with Paleolithic paintings and surrounding rock walls in two Spanish caves (Llonín and La Garma). FEMS Microbiol Ecol (2004) 0.99
Patient perceptions of open and arthroscopic shoulder surgery. Arthroscopy (2007) 0.98
Bacterial ghosts as adjuvant particles. Expert Rev Vaccines (2007) 0.98
Recent insights into microbial triggers of interleukin-10 production in the host and the impact on infectious disease pathogenesis. FEMS Immunol Med Microbiol (2012) 0.98
The anti-inflammatory effects of acupuncture and their relevance to allergic rhinitis: a narrative review and proposed model. Evid Based Complement Alternat Med (2013) 0.97
Evaluation of the protective efficacy of Vibrio cholerae ghost (VCG) candidate vaccines in rabbits. Vaccine (2003) 0.96
Bacterial ghosts as antigen delivery vehicles. Adv Drug Deliv Rev (2005) 0.96
Agrococcus baldri sp. nov., isolated from the air in the 'Virgilkapelle' in Vienna. Int J Syst Evol Microbiol (2002) 0.95
RuleBender: a visual interface for rule-based modeling. Bioinformatics (2011) 0.95
Antigen discovery and delivery of subunit vaccines by nonliving bacterial ghost vectors. Expert Rev Vaccines (2004) 0.95
Comparative immunogenicity of the hepatitis B virus core 149 antigen displayed on the inner and outer membrane of bacterial ghosts. Vaccine (2005) 0.95
Epithelial cell coculture models for studying infectious diseases: benefits and limitations. J Biomed Biotechnol (2011) 0.94
Otitis media: viruses, bacteria, biofilms and vaccines. Med J Aust (2009) 0.94
Vaccines for otitis media: proposals for overcoming obstacles to progress. Vaccine (2005) 0.94
Bacterial ghosts are an efficient delivery system for DNA vaccines. J Immunol (2004) 0.93
Functional differences between M cells and enterocytes in sampling luminal antigens. Vaccine (2008) 0.92
Applications of bacterial ghosts in biomedicine. Adv Exp Med Biol (2009) 0.91
The "moving valgus stress test" for medial collateral ligament tears of the elbow. Am J Sports Med (2005) 0.90
Comparison of mucosal and parenteral immunisation in two animal models of pneumococcal infection: otitis media and acute pneumonia. Vaccine (2006) 0.89
Post-exposure passive immunisation for preventing measles. Cochrane Database Syst Rev (2014) 0.89
Mucosal immunization: a realistic alternative. Hum Vaccin (2010) 0.88
Recent advances in otitis media. 6. Vaccine. Ann Otol Rhinol Laryngol Suppl (2005) 0.88
DNA-loaded bacterial ghosts efficiently mediate reporter gene transfer and expression in macrophages. Mol Ther (2005) 0.87
Bacterial ghosts as carriers of protein subunit and DNA-encoded antigens for vaccine applications. Expert Rev Vaccines (2012) 0.86
Minicircle DNA immobilized in bacterial ghosts: in vivo production of safe non-viral DNA delivery vehicles. J Mol Microbiol Biotechnol (2004) 0.86
Mucosal immunisation with novel Streptococcus pneumoniae protein antigens enhances bacterial clearance in an acute mouse lung infection model. FEMS Immunol Med Microbiol (2005) 0.86
Bacillus barbaricus sp. nov., isolated from an experimental wall painting. Int J Syst Evol Microbiol (2003) 0.86
Characterization of a novel porin protein from Moraxella catarrhalis and identification of an immunodominant surface loop. J Bacteriol (2005) 0.86
Bacterial ghosts--biological particles as delivery systems for antigens, nucleic acids and drugs. Curr Opin Biotechnol (2004) 0.85
Investigation of an anaerobic microbial community associated with a corneal ulcer by denaturing gradient gel electrophoresis and 16S rDNA sequence analysis. Diagn Microbiol Infect Dis (2002) 0.85
Altamira cave Paleolithic paintings harbor partly unknown bacterial communities. FEMS Microbiol Lett (2002) 0.85
Bacterial ghosts as novel efficient targeting vehicles for DNA delivery to the human monocyte-derived dendritic cells. J Immunother (2005) 0.85
Probiotics supplementation for athletes - clinical and physiological effects. Eur J Sport Sci (2014) 0.85
Immobilization of plasmid DNA in bacterial ghosts. J Control Release (2005) 0.85
Antimicrobial peptides and proteins, exercise and innate mucosal immunity. FEMS Immunol Med Microbiol (2006) 0.84
Bacterial ghosts as novel advanced drug delivery systems: antiproliferative activity of loaded doxorubicin in human Caco-2 cells. J Control Release (2004) 0.84
Bacterial ghosts (BGs)--advanced antigen and drug delivery system. Vaccine (2010) 0.84
Interaction between probiotic lactic acid bacteria and canine enteric pathogens: a risk factor for intestinal Enterococcus faecium colonization? Vet Microbiol (2003) 0.84
Modulation of gene expression by promoter mutants of the lambdacI857/pRM/pR system. J Biotechnol (2004) 0.84
Sealed bacterial ghosts--novel targeting vehicles for advanced drug delivery of water-soluble substances. J Drug Target (2003) 0.84
Development of mucosal immunity in the first year of life and relationship to sudden infant death syndrome. FEMS Immunol Med Microbiol (2004) 0.84
Post-exposure passive immunisation for preventing rubella and congenital rubella syndrome. Cochrane Database Syst Rev (2015) 0.84
Bacterial Ghosts as antigen and drug delivery system for ocular surface diseases: Effective internalization of Bacterial Ghosts by human conjunctival epithelial cells. J Biotechnol (2011) 0.83
Bacterial ghosts as a novel advanced targeting system for drug and DNA delivery. Expert Opin Drug Deliv (2006) 0.83
Receptor mediated targeting of M-cells. Vaccine (2007) 0.83
Microbacterium aerolatum sp. nov., isolated from the air in the 'Virgilkapelle' in Vienna. Int J Syst Evol Microbiol (2002) 0.82
Humeral head fracture-dislocation into the thoracic outlet: case report and review of the literature. J Shoulder Elbow Surg (2004) 0.82
Citricoccus muralis gen. nov., sp. nov., a novel actinobacterium isolated from a medieval wall painting. Int J Syst Evol Microbiol (2002) 0.82
In vitro and in vivo uptake study of Escherichia coli Nissle 1917 bacterial ghosts: cell-based delivery system to target ocular surface diseases. Invest Ophthalmol Vis Sci (2013) 0.82
Vaccination against respiratory Pseudomonas aeruginosa infection. Hum Vaccin Immunother (2014) 0.81
Bacterial ghosts as a delivery system for zona pellucida-2 fertility control vaccines for brushtail possums (Trichosurus vulpecula). Vaccine (2008) 0.81
Natural products and the search for novel vaccine adjuvants. Vaccine (2011) 0.81
T cell-specific immune response induced by bacterial ghosts. Med Sci Monit (2004) 0.81
Moraxella catarrhalis M35 is a general porin that is important for growth under nutrient-limiting conditions and in the nasopharynges of mice. J Bacteriol (2008) 0.81
Immunity, immunopathology, and human vaccine development against sexually transmitted Chlamydia trachomatis. Hum Vaccin Immunother (2014) 0.81
Proteomics and bioinformatics strategies to design countermeasures against infectious threat agents. J Chem Inf Model (2006) 0.80
Are vaccination models suitable to determine whether probiotics have beneficial health effects in the general population? Hum Vaccin Immunother (2013) 0.80
Georgenia muralis gen. nov., sp. nov., a novel actinobacterium isolated from a medieval wall painting. Int J Syst Evol Microbiol (2002) 0.80
Mucosal immunization against respiratory bacterial pathogens. Expert Rev Vaccines (2003) 0.80
Effectiveness of engineering the nontypeable Haemophilus influenzae antigen Omp26 as an S-layer fusion in bacterial ghosts as a mucosal vaccine delivery. Hum Vaccin (2011) 0.80
Iron-regulated lysis of recombinant Escherichia coli in host releases protective antigen and confers biological containment. Infect Immun (2011) 0.80
Rectal single dose immunization of mice with Escherichia coli O157:H7 bacterial ghosts induces efficient humoral and cellular immune responses and protects against the lethal heterologous challenge. Microb Biotechnol (2011) 0.79